Literature DB >> 26807186

Effects of siRNA-mediated silencing of myeloid cell leukelia-1 on the biological behaviors and drug resistance of gastric cancer cells.

Bo-Pei Li1, Jin-Lu Liu1, Jun-Qiang Chen1, Zhen Wang1, Yuan-Tian Mao1, Ye-Yang Chen1.   

Abstract

OBJECTIVE: This study was to investigate the effects of siRNA mediated silencing of myeloid cell leukelia-1 (Mcl-1) on the biological behaviors and drug resistance of human drug-resistant gastric cancer (GC) cell lines, and to explore the potential mechanisms.
METHODS: siRNA targeting Mcl-1 mRNA were designed and independently transfected into SGC-7901/VCR and SGC-7901/DDP. Cell proliferation and drug sensitivity were examined by MTT assay. Cell apoptosis and cell cycle were detected by flow cytometry. Cell Invasion and migration abilities were detected by transwell chamber assays. The expressions of drug-resistance-related genes and apoptosis-related proteins were detected by quantitative real-time PCR and Western blot assay, respectively.
RESULTS: siRNA effectively inhibited the Mcl-1 expression, lowered the proliferation rate (P<0.05), raised the apoptosis rate (P<0.05), and arrested cells in S-phase (P<0.05). After inhibiting Mcl-1, the cell migration and invasion decreased (P<0.05), the resistance to VCR, DDP and 5-Fu was reversed to different extents (P<0.05), TS mRNA expression increased significantly (P<0.05), MDR1 remained unchanged (P>0.05), but DPD and TOP2A decreased significantly (P<0.05). Following Mcl-1 silencing, Bcl-2 was over-expressed in VCR-siRNA group, but the expressions of Fas and survivin reduced markedly (P<0.05); Bcl-2 and Fas expressions decreased significantly in DDP-siRNA group (P<0.05), but survivin expression remained unchanged.
CONCLUSION: Mcl-1 is implicated in the proliferation, invasion, apoptosis and drug resistance of GC cells, and may be a promising target for the therapy of GC.

Entities:  

Keywords:  Myeloid cell leukelia-1 gene; drug resistance; gastric cancer; mechanism; siRNA

Year:  2015        PMID: 26807186      PMCID: PMC4697718     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  31 in total

1.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.

Authors:  K M Kozopas; T Yang; H L Buchan; P Zhou; R W Craig
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

2.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Down-regulation of ICBP90 contributes to doxorubicin resistance.

Authors:  Jingxuan Wang; Ying Song; Shanqi Xu; Qingyuan Zhang; Yulian Li; Dabei Tang; Shi Jin
Journal:  Eur J Pharmacol       Date:  2011-02-04       Impact factor: 4.432

4.  Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.

Authors:  Gongquan Li; Shuijun Zhang; Hongbo Fang; Bing Yan; Yongfu Zhao; Liushun Feng; Xiuxian Ma; Xuexiang Ye
Journal:  Biochem Biophys Res Commun       Date:  2013-04-20       Impact factor: 3.575

5.  ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.

Authors:  Maria Russo; Carmela Spagnuolo; Silvestro Volpe; Idolo Tedesco; Stefania Bilotto; Gian Luigi Russo
Journal:  Biochem Pharmacol       Date:  2013-01-24       Impact factor: 5.858

6.  Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1.

Authors:  Shogo Kobayashi; Sun-Hee Lee; Xue W Meng; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Ruth W Craig; Scott H Kaufmann; Gregory J Gores
Journal:  J Biol Chem       Date:  2007-04-25       Impact factor: 5.157

7.  MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.

Authors:  Rui-Yan Li; Ling-Chao Chen; Hai-Yan Zhang; Wen-Zhong Du; Yan Feng; Han-Bing Wang; Jin-Qiong Wen; Xin Liu; Xian-Feng Li; Ying Sun; Dong-Bo Yang; Tao Jiang; Yong-Li Li; Chuan-Lu Jiang
Journal:  CNS Neurosci Ther       Date:  2013-04-02       Impact factor: 5.243

8.  A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy.

Authors:  W J Placzek; J Wei; S Kitada; D Zhai; J C Reed; M Pellecchia
Journal:  Cell Death Dis       Date:  2010-05-06       Impact factor: 8.469

Review 9.  Current prospects for RNA interference-based therapies.

Authors:  Beverly L Davidson; Paul B McCray
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

10.  Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.

Authors:  Bruno Christian Koehler; Anna-Lena Scherr; Stephan Lorenz; Toni Urbanik; Nicole Kautz; Christin Elssner; Stefan Welte; Justo Lorenzo Bermejo; Dirk Jäger; Henning Schulze-Bergkamen
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.